Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 360 Print this page  Email this page Small font size Default font size Increase font size
Year : 2011  |  Volume : 26  |  Issue : 4  |  Page : 165-170

Tc-99m glucoheptonate is poor man's fluorodeoxyglucose

Department of Nuclear Medicine and Radioimmunoassay, Lilavati Hospital and Research Centre, Department of Nuclear Medicine and PET-CT, Jaslok Hospital and Research Centre, Mumbai, India

Correspondence Address:
Ramchandra D Lele
Department of Nuclear Medicine, Lilavati Hospital and Research Centre, Mumbai - 400 050, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0972-3919.106678

Rights and Permissions

While fluoro-deoxy-glucose (FDG) has emerged as an important radiotracer for imaging tumors, myocardial viability and infection, the role of other glucose analogues should also be explored. Tc-99m Glucoheptonate (GHA) has been used for imaging brain tumors and lung tumors. The uptake mechanism may be linked to GLUT-1 (Glucose transporter) and GLUT-4 expression similar to FDG. GHA is easily available and cheap. With the availability of single photon emission computed tomography/computed tomography (SPECT/CT), GHA imaging should be re-explored as a tumor agent and also for imaging myocardial viability.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded164    
    Comments [Add]    

Recommend this journal